Friday Apr 18
Johnson & Johnson Starts Construction On $300 Million China Plant
For J&J, the new facility is its biggest single investment in a plant and its largest production facility .
Trending on the Topix Network
Friday Apr 18
Belgium digestive remedies market: Janssen-Cilag the dominant industry player during 2012
Janssen-Cilag was the undisputed leader in a fragmented competitive environment in the Belgium digestive remedies market in 2012.
Thu Apr 17, 2014
How your green business can encourage consumers to recycle
Nearly three-quarters of consumers consistently recycle in the home, but only about half do so in rooms beyond the kitchen.
Argus Increases Johnson & Johnson Price Target to $116.00
The firm currently has a "buy" rating on the stock. Argus' target price suggests a potential upside of 16.94% from the stock's previous close.
Wed Apr 16, 2014
The Motley Fool
Is Johnson & Johnson's Dividend Unbeatable?
Major health-care stocks out of big pharma and medical devices offer great dividends, but few offer the strength and reliability of sector colossus Johnson & Johnson .
Contract Pharma Breaking News
Financial Report: Johnson & Johnson 1Q
Johnson & Johnson 1Q Revenues: $18.1 billion 1Q Earnings: $4.7 billion Comments: Worldwide pharmaceutical sales were $7.5 billion, up 11%, driven by STELARA, INVEGA, SUSTENNA/XEPLION, PREZISTA, and VELCADE, as well as new products OLYSIO/SOVRIAD, a combination treatment of chronic hepatitis C, and ZYTIGA for the treatment of prostate cancer.
Smartphone apps to help patients take their meds
Several smartphone apps are available to help patients take their medications as prescribed.
Earnings Outlook is the Key Factor - Ahead of Wall Street
The benign inflation reading and a soft Empire State manufacturing survey are the only notable economic reports today.
Tue Apr 15, 2014
Investor's Business Daily
Major Averages Reverse Early Losses In Higher Volume
Tuesday was shaping up to be another ugly day for the stock market, but major averages recovered impressively and closed near highs on a busy day of headline flow.
Taiwan baby products market: Johnson & Johnson and BA1 4bchen the...
These include Johnson & Johnson, BA1 4bchen, Sebamed, Chicco and Pigeon, which together accounted for 71% of total sales in 2012.
Johnson & Johnson (JNJ) Updates FY14 Earnings Guidance
Johnson & Johnson issued an update on its FY14 earnings guidance on Tuesday morning.
Johnson & Johnson's Q1 profit rises 8 pct on lower spending, surge in prescription drug sales
Johnson & Johnson says its first-quarter profit rose 8 per cent, because of restrained costs and a big jump in prescription drug sales.
Mon Apr 14, 2014
Johnson & Johnson Innovation Center Joins Advance Drug Discovery Effort
The Scripps Research Institute has joined with Johnson & Johnson Innovation Center and other partners to launch a new drug discovery effort designed to translate early-stage biomedical research projects into new treatments.
Johnson & Johnson (JNJ) to Release Quarterly Earnings on Tuesday
Johnson & Johnson is scheduled to be announcing its Q114 earnings results on Tuesday, April 15th.
Fri Apr 11, 2014
Forbes Earnings Preview: Johnson & Johnson
Johnson & Johnson reports its first-quarter earnings on Tuesday, April 15, 2014, and the consensus earnings per share estimate is $1.48 per share.
Tue Apr 08, 2014
Avon Ditches Triclosan
Avon has announced plans to phase out the antibacterial chemical triclosan from its cosmetic and personal care products, the company has announced.
Wed Apr 02, 2014
Why Johnson & Johnson Treasures BabyCenter's Data
Johnson & Johnson has improved on its ability to target its advertising and develop brand strategies thanks to some internal initiatives .
Medical Device/Diagnostic Ind.
What Does JNJ's $4B Divestiture of Its Diagnostics Business Mean for the IVD Segment in MedTech?
In order to focus on its core business of consume products, pharmaceuticals and devices, Johnson & Johnson has been assiduously reviewing its business segments, and pruning them as needed.
Tue Apr 01, 2014
What Can Investors Expect Of Johnson & Johnson's Dividend Going Forward?
Johnson & Johnson has shown a strong commitment to returning capital to shareholders with a 51-year streak of dividend increases.
Mon Mar 31, 2014
The Verona-Cedar Grove Times
J&J accepts Carlyle's offer buy diagnostics division
Johnson & Johnson accepted the $4 billion offer from Carlyle Group LP made in January to buy the health care products company's only diagnostics division.